Genovis Q3 2022: Initial Take Positive – Beat on EBIT - Redeye

Redeye provides its initial take on Genovis’ Q3 2022 report, which came in just below our expectations on sales but significantly above our EBIT estimate. The impact of the COVID-19 pandemic is easing, and Genovis saw growth in all geographic markets. We consider this a strong report from Genovis.

Länk till analysen i sin helhet: https://www.redeye.se/research/863393/genovis-q3-2022-initial-take-positive-beat-on-ebit?utm_source=finwire&utm_medium=RSS